FDA issued an Early Alert for Abiomed's Automated Impella Controllers due to potential safety concerns following reports of 3 ...

Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety concerns, the MedTech giant announced.

Johnson & Johnson paused the U.S. rollout of its Varipulse heart device after stroke reports. The pause follows four stroke events, affecting patients in the U.S. and Europe.

Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety concerns, the MedTech giant announced ...

Johnson & Johnson (NYSE: JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets ...

Johnson & Johnson MedTech has received the US Food and Drug Administration (FDA) approval for its VARIPULSE Platform to treat drug-refractory paroxysmal atrial fibrillation (AFib). This system is ...

Johnson & Johnson announced that on January 5, "out of an abundance of caution," Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. Varipulse cases while it ...

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE™ Platform for the treatment of ...

Johnson & Johnson said on Wednesday it had temporarily paused the rollout of its Varipulse heart device in the United States, as the company investigates four reported stroke events.

IRVINE, Calif., Nov. 7, 2024 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U.S. Food & Drug Administration (FDA) approval of the ...